highly significantP < 0.05
By day 15, SC-RP-treated groups still maintained better motility and presented highly significant dose-dependent differences ( P < 0.05).
By day 15, SC-RP-treated groups still maintained better motility and presented highly significant dose-dependent differences ( P < 0.05).